RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sutro Biopharma - Stock

Sutro Biopharma ROCE 2024

Sutro Biopharma ROCE

-0.6

Ticker

STRO

ISIN

US8693671021

WKN

A2N6SG

In 2024, Sutro Biopharma's return on capital employed (ROCE) was -0.6, a 0.4% increase from the -0.59 ROCE in the previous year.

Sutro Biopharma Aktienanalyse

What does Sutro Biopharma do?

Sutro Biopharma Inc. is a biopharmaceutical company founded in 2003 by Dr. William James Sutro. The company is headquartered in South San Francisco, California and aims to develop biotech tools and platforms that accelerate and facilitate the manufacture of innovative therapeutics. Sutro Biopharma's business model focuses on creating drug candidates based on proprietary technologies. The company does not rely on conventional biological systems or cells typically used for protein expression and drug manufacturing. Instead, it has developed a platform for protein synthesis that allows for targeted and effective production of specific proteins. The main focus of Sutro Biopharma Inc. is cancer research and improved cancer therapy. Various business areas have been established for this purpose. In the field of oncology, Sutro Biopharma is involved in the development of immunotherapeutic agents such as bi-specific antibodies that are of interest for many types of cancer due to their high selectivity and efficacy. A special feature of Sutro Biopharma is the production of many therapeutic proteins as so-called conjugated proteins. This means that special bioactive molecules are attached to the surface of the therapeutic protein. These conjugated proteins enable targeted and enhanced drug effects. The STRO-001 program is an example of this type of conjugate and is one of the most promising products of Sutro Biopharma. STRO-001 is an antibody designed specifically for the recognition of tumor-associated CD74 proteins. These CD74 surface proteins are expressed by many cancer cells and therefore serve as ideal targets for cancer therapy. The STRO-001 antibody is delivered as a conjugate into the cancer cells, where it releases the toxic molecule calicheamicin, which ensures targeted destruction of the cancer cell. In addition to developing conjugated proteins for cancer research, Sutro Biopharma is also involved in combating autoimmune diseases such as rheumatoid arthritis. The XpressCF+ program has been launched for this purpose, which aims to facilitate the production of autoantibodies for novel therapeutics. Another division of Sutro Biopharma Inc. focuses on drug development for rare diseases. The company particularly focuses on proteolytic enzymes that could serve as targets for the development of new therapeutics for rare metabolic diseases. The goal is to expand the treatment options for many of these unexplored diseases through the development of innovative therapies. Overall, Sutro Biopharma Inc. has become an important company within the biotech industry in recent years, making significant contributions to cancer therapy and other serious diseases through its effective biotechnological tools and dedicated research efforts. The company is crucial in improving treatment possibilities for cancer and many other severe diseases. Sutro Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Sutro Biopharma's Return on Capital Employed (ROCE)

Sutro Biopharma's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Sutro Biopharma's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Sutro Biopharma's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Sutro Biopharma’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Sutro Biopharma Stock

What is the ROCE (Return on Capital Employed) of Sutro Biopharma this year?

The ROCE of Sutro Biopharma is -0.6 undefined this year.

How has the ROCE (Return on Capital Employed) of Sutro Biopharma developed compared to the previous year?

The ROCE of Sutro Biopharma has increased by 0.4% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Sutro Biopharma?

A high Return on Capital Employed (ROCE) indicates that Sutro Biopharma has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Sutro Biopharma?

A low ROCE (Return on Capital Employed) can indicate that Sutro Biopharma has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Sutro Biopharma impact the company?

An increase in the ROCE of Sutro Biopharma can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Sutro Biopharma affect the company?

A decrease in ROCE of Sutro Biopharma can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Sutro Biopharma?

Some factors that can affect Sutro Biopharma's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Sutro Biopharma so important for investors?

The ROCE of Sutro Biopharma is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Sutro Biopharma take to improve the ROCE?

To improve the ROCE, Sutro Biopharma can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Sutro Biopharma pay?

Over the past 12 months, Sutro Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sutro Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Sutro Biopharma?

The current dividend yield of Sutro Biopharma is .

When does Sutro Biopharma pay dividends?

Sutro Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sutro Biopharma?

Sutro Biopharma paid dividends every year for the past 0 years.

What is the dividend of Sutro Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sutro Biopharma located?

Sutro Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sutro Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sutro Biopharma from 6/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/26/2024.

When did Sutro Biopharma pay the last dividend?

The last dividend was paid out on 6/26/2024.

What was the dividend of Sutro Biopharma in the year 2023?

In the year 2023, Sutro Biopharma distributed 0 USD as dividends.

In which currency does Sutro Biopharma pay out the dividend?

The dividends of Sutro Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sutro Biopharma

Our stock analysis for Sutro Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sutro Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.